A transdermal drug delivery systems (TDDS) is a medicated adhesive bandage or a patch that is stuck onto the skin to deliver a dose of drug through the skin and in the bloodstream. This patch promotes faster healing of injuries on the body, delivers a steady infusion of the drug over a time period and increases the therapeutic value of drugs by avoiding problem associated with drug. This is a simple technique in which the patch is placed on the injured part of body, from where the drug slowly penetrates in to the skin and it heals the injured part.
The advantages of transdermal drug delivery system are – it is non-invasive, less painful to the patient,administration of complete dose , provides controlled plasma level of the potent drugs, termination of therapy is easy at any time if not necessary, it is a cost effective treatment and the bandage or patch is removable. The main components of TDDS are liner, drug, adhesive, membrane, blacking, matrix filler, and permeation enhancer. The types of TDDS includes single layer drug in adhesive, multi-layer drug in adhesive, reservoir, vapor and matrix.
The technological advancement in transdermal drug delivery system is anticipated to serve the market growth in the near future. The advance technology includes transdermal patch design modification, incorporation of pressure sensitive adhesives and permeation enhancers that results in the enhancement of drug diffusion and increased the capacity to hold the drug in excess amount.
Request a sample copy of this [email protected]
Rise in number of surgical procedures around the globe and increase in prevalence of cardiovascular disorders is expected to further bolster the transdermal drug delivery system market growth
North America and Asia Pacific are expected to lead the highest growth in transdermal drug delivery system market due to the rise in emergency medical cases and the increase of surgical procedures. As per the World Health Organization (WHO), the global surgical volume in 2012 was around 312.9 million. The cardiovascular disorders are expected to grow at an exponential stage during the forecast period, that can be attributed to increase the utilization of transdermal drug delivery systems. According to the American Heart Association, it was estimated that the incident of heart attack in the U.S. was around 58000 in 2014, and in 2013 worldwide prevalence of stroke was around 25.7 million. Also as per the World Health Organization (WHO), it was estimated that in 2015, around 17.7 million people died from cardiovascular diseases (CVDs) including around 31% of global deaths and among this, around 7.4% had coronary heart disease.
The growth in various type of diseases such as skin ulcer, acne and skin rash leads the exponential growth of surgical procedures and hence, this surgeries growth can be attributed to increase in utilization of transdermal drug delivery systems. As per World Health Organization (WHO), the global surgical volume in 2012 was around 312.9 million, as the estimated mean global surgical rate was 4469 operations per 100 000 people every year.
Transdermal Drug Delivery Systems Market by Key Player Includes:
Therapeutics Inc., ALLERGAN, Endo International plc, GlaxoSmithKline plc, Hisamitsu Pharmaceutical Co.Inc., IBSA Institut Biochimque SA, Mylan N.V. , Pfizer, Inc., TEH SENG Pharmaceutical Mfg. Co., Ltd., and Teikoku Seiyaku Co., Ltd., 3M Pharmaceuticals Inc., Actelion Pharmaceuticals Ltd, Bayer Crop Science Ltd., BioGel Technology Inc., Upsher-Smith Laboratories, Inc., Johnson & Johnson Limited, Mylan Pharmaceuticals Inc., Novartis AG, Janssen Pharmaceuticals, Inc., Noven Pharmaceuticals Inc., Boehringer Ingelheim GmbH and Actavis Inc.
Get Table Of Content: